Mirum Pharma Executive Compensation Details Released
Ticker: MIRM · Form: DEF 14A · Filed: Apr 14, 2025 · CIK: 1759425
Sentiment: neutral
Topics: executive-compensation, proxy-statement, equity-awards
TL;DR
Mirum Pharma dropped its proxy statement detailing exec pay for 2024 - check out the equity awards.
AI Summary
Mirum Pharmaceuticals, Inc. filed its DEF 14A on April 14, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on equity awards granted to both principal executive officers (PEO) and non-PEO/NEO individuals, with data points on year-end fair value of outstanding awards and changes in fair value.
Why It Matters
This filing provides transparency into how Mirum Pharmaceuticals compensates its top executives, which can influence investor perception and employee morale.
Risk Assessment
Risk Level: low — This is a routine DEF 14A filing providing information on executive compensation and does not indicate any immediate financial distress or significant operational changes.
Key Numbers
- 2024 — Fiscal Year (Reporting period for executive compensation)
- 2023 — Fiscal Year (Comparative financial data period)
- 2022 — Fiscal Year (Comparative financial data period)
Key Players & Entities
- Mirum Pharmaceuticals, Inc. (company) — Filer of the DEF 14A
- April 14, 2025 (date) — Filing date of the DEF 14A
- December 31, 2024 (date) — Fiscal year end for compensation reporting
FAQ
What is the total value of equity awards granted to PEOs in 2024?
The filing provides data on the year-end fair value of equity awards granted in covered years outstanding and unvested for PEO members, but a specific total dollar amount for 2024 grants is not immediately calculable from the provided snippet.
How did the fair value of outstanding equity awards change for non-PEO/NEO members in 2024?
The filing indicates there were changes in the fair value of outstanding and unvested equity awards granted in prior years for non-PEO/NEO members during the 2024 fiscal year.
What is the company's Standard Industrial Classification (SIC) code?
The SIC code for Mirum Pharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
When was Mirum Pharmaceuticals, Inc. incorporated?
The state of incorporation for Mirum Pharmaceuticals, Inc. is Delaware (DE).
What is the business address of Mirum Pharmaceuticals, Inc.?
The business address is 989 East Hillsdale Boulevard, Suite 300, Foster City, CA 94404.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 14, 2025 regarding Mirum Pharmaceuticals, Inc. (MIRM).